Satraplatin in Hormone-Refractory Prostate Cancer and Other Tumour Types: Pharmacological Properties and Clinical Evaluation

Author： McKeage Mark J.

Publisher： Adis International

ISSN： 0012-6667

Source： Drugs, Vol.67, Iss.6, 2007-01, pp. : 859-869

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

The Battle Against Hormone-Refractory Prostate Cancer: Is Satraplatin the Second-Line Savior?

By Adis International Limited

Pharmaceutical & Diagnostic Innovation, Vol. 4, Iss. 5, 2006-01 ,pp. : 7-9

Adis International

Access to resources Recommend Favorite

Which drug combination for hormone-refractory prostate cancer?

By Doggrell Sheila A

Expert Opinion on Pharmacotherapy, Vol. 6, Iss. 4, 2005-04 ,pp. : 667-670

Informa Healthcare

Access to resources Recommend Favorite

Cabazitaxel: A Novel Drug for Hormone-Refractory Prostate Cancer

Mini Reviews in Medicinal Chemistry, Vol. 13, Iss. 6, 2013-05 ,pp. : 915-920

Bentham Science Publishers

Access to resources Recommend Favorite

Docetaxel: In Hormone-Refractory Metastatic Prostate Cancer

By McKeage Kate Keam Susan J.

Drugs, Vol. 65, Iss. 16, 2005-01 ,pp. : 2287-2294

Adis International

Access to resources Recommend Favorite

Satraplatin shows benefit in refractory prostate cancer

Inpharma, Vol. 1, Iss. 1641, 2008-01 ,pp. : 4-4

Adis International

Access to resources Recommend Favorite